ELI Lilly and Boehringer
Ingelheim have entered into a
strategic alliance to develop and
commercialise new diabetes drugs.
Under the agreement the pair
will jointly develop and
commercialise a portfolio of
diabetes compounds currently in
mid- and late-stage development.
At present the agreement covers
Boehringer Ingelheim’s two oral
diabetes agents, linagliptin and
BI10773, and Lilly’s two basal
insulin analogues, LY2605541 and
LY2963016, as well as the option
to co-develop and co-commercialise
Lilly’s anti-TGF-beta monoclonal
antibody.The above article was sent to subscribers in Pharmacy Daily's issue from 14 Jan 11 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Jan 11
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.